Hepatoprotective Effects of Reishi Mushroom- (Ganoderma Lucidum) Among Metabolic Dysfunction-associated Fatty Liver Disease Patients

Inclusion Criteria: * Adults aged 35-65 years * BMI between 18.5 and 30 kg/m². * Complete Blood Count test ranges, WBC \< 4,000-11,000 cells/µL, RBC Men \< 4.5-6.0 / Women 4.0-5.5 million/µL, Hemoglobin: Men \< 13.5-17.5 / Women 12.0-15.5 g/dL, Platelets \< 150,000-450,000 cells/µL. * Lipid profile test markers (elevated LDL, total cholesterol, or triglycerides less than 150mg/dL high 200-499mg/dL and 500 mg/dL are above high. * Liver function test markers, ALT \> 56 U/L, AST\>40 U/L, ALP\>147 UL. * Inflammatory markers: CRP \>3 mg/L, - IL-6 ≥3 pg/mL, TNF-α ≥8 pg/mL. * Elevated blood sugar levels, or hyperglycemia, refer to a typically above 126 mg/dL, fasting or 200 mg/dL post-meal. Exclusion Criteria: * ● Diagnosed with severe cardiovascular disease, liver failure, or renal impairment. * Pregnant or lactating women. * Individuals currently on statins, ezetimibe, PCSK9 inhibitors, or any other lipid-lowering therapy. * Allergic to mushrooms. * Diagnosed with celiac disease or other chronic gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis). * History of malignancy. * Participation in another clinical trial within the last 3 months.